Physician profile
Mark D Crowley
NPI 1568442481
$3,838.04
in general payments reported to CMS, 2019-2025
33 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $1,183 · 2021: $1,580 · 2022: $286 · 2023: $14.46 · 2024: $139 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $384.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $531.95 | 2019-2022 | |
| Astellas Pharma US INC | $523.72 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $432.84 | 2020-2024 | Airsupra |
| Abbvie INC. | $362.70 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $355.89 | 2019-2021 | |
| Amarin Pharma, INC. | $346.63 | 2019-2021 | |
| Pfizer INC. | $310.75 | 2020-2022 | |
| Glaxosmithkline, LLC. | $119.39 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $87.77 | 2019-2022 | |
| Axsome Therapeutics, INC. | $83.25 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $75.63 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $65.25 | 2019-2022 | |
| Corcept Therapeutics | $58.10 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.82 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.80 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $45.73 | 2024-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $39.01 | 2024-2025 | |
| Lilly USA, LLC | $27.98 | 2022 | |
| Eisai INC. | $27.76 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.72 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $24.37 | 2024-2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $23.13 | 2020-2021 | |
| Abbott Laboratories | $19.13 | 2021 | |
| Merck Sharp & Dohme LLC | $17.75 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.13 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.67 | 2021 | |
| Covis Pharma Gmbh | $14.46 | 2023 | |
| Dexcom, INC. | $14.35 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.00 | 2021 | |
| Amneal Pharmaceuticals LLC | $12.33 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $11.94 | 2020 | |
| Mylan Specialty L.P. | $11.76 | 2020 | |
| Avanir Pharmaceuticals, INC. | $11.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Crowley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.